Acne :: Stubborn truth about Acne
New Survey and Studies Debunk the Myths and Misconceptions About this Common Skin Condition
Month: July 2005
HIV :: Silicon Reverses Facial Wasting in AIDS Patients
AIDS patients with a disfiguring skin complication caused by HIV infection can be treated safely and successfully with applications of an inexpensive silicone oil preparation, according to research reported in Dermatologic Surgery, the medical journal of the American Society for Dermatologic Surgery (ASDS).
Skin Care :: SCULPTRA for facial fat loss – lipoatrophy
The U.S. Food and Drug Administration (FDA) advisory committee recently approved SCULPTRA (injectable poly-L-lactic acid) for use in correcting shape and contour deficiencies resulting from facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV).
Acne :: Photodynamic Therapy – Treatment of Acne, Rosacea and Sun Damage
Acne, rosacea and sun damage are some of the most prevalent skin conditions treated by dermatologists. Fortunately, recent advances in laser therapies are providing new hope for millions of people who struggle with these conditions everyday.
Epilepsy :: New indication for Topamax for adults and children with epilepsy
The US Food and Drug Administration (FDA) approved a new use for TOPAMAX (topiramate) Tablets and TOPAMAX (topiramate capsules) Sprinkle Capsules as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.
Acne :: Millions of women facing adult acne
For all too many women, the acne that they once feared would flare up just in time for prom as a teenager has resurfaced into their adult years – causing anxiety for events from weddings to job interviews. The reason? Chronic, persistent acne is a common medical condition for women who either have suffered with it since adolescence or for those who first develop it during adulthood. Either way, the physical and emotional toll that acne causes can be devastating.
ADHD :: FDA Gets Tough on ADHD Drugs
Citing concerns about possible psychiatric side effects, the FDA said it will add new label warnings to a class of drugs used to treat attention-deficit hyperactivity disorder (ADHD).